Skip to main content
SpringerLink
Log in

Immunohistochemical evidence that P-glycoprotein in non-small cell lung cancers is associated with shorter survival

  • Original Articles
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

The expression of P-glycoprotein in 159 non-small cell lung cancers was immunohistochemically examined using a monoclonal antibody (MoAb C219). A total of 93 (60%) cancers were found to be positive for P-glycoprotein. The 5-year survival rates of patients with P-glycoprotein (P-gp+) and those without P-glycoprotein (P-gp−) were 47.6% and 73.6%, respectively (P<0.05). According to a univariate analysis, P-gp+ was associated with a poor prognosis for males, those with stage I cancer, those who underwent complete resection, and those with adenocarcinoma or squamous cell carcinoma. A multivariate study using the Cox regression analysis indicated that the expression of P-glycoprotein is useful for predicting the prognosis. Among 24 patients who underwent complete resection and postoperative adjuvant chemotherapy, 18 were P-gp+ and the remaining 6 were P-gp−. Of the 18 with P-gp+ cancer, 11 relapsed and 9 died from tumor-related causes, while the other 7 remain free from tumor recurrence; however, all with P-gp− cancer are alive without recurrence. These observations suggest a bias toward a shorter survival for patients with P-gp+ cancer because P-glycoprotein may be associated with chemoresistance. Thus, detection of the expression of P-glycoprotein will aid in planning appropriate adjuvant chemotherapy for patients with non-small cell lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ministry of Health and Welfare (1995) Vital statistics of Japan 1993, vol. 3. Ministry of Health and Welfare, Japan

    Google Scholar 

  2. Ishida T, Yokoyama H, Kaneko S, Sugio K, Sugimachi K (1990) Long-term results of operation for non-small cell lung cancer in the elderly. Ann Thorac Surg 50:919–922

    Article  CAS  PubMed  Google Scholar 

  3. Ishida T, Yano T, Maeda K, Kaneko K, Tateishi M, Sugimachi K (1990) Strategy for lymphadenectomy in lung cancer; three centimeters or less in diameter. Ann Thorac Surg 50:708–713

    Article  CAS  PubMed  Google Scholar 

  4. Tsubota N, Yoshimura M (1996) Skip metastasis and hidden N2 disease in lung cancer: how successful is mediastinal dissection? Surg Today 26:169–172

    Article  CAS  PubMed  Google Scholar 

  5. Mountain C (1986) A new international staging system for lung cancer. Chest 89 (Suppl.):225s-233s

    CAS  PubMed  Google Scholar 

  6. Homes EC, Hill LD, Gail M (1985) A randomized comparison of the effect of adjuvant therapy on resected stage II and stage III non-small cell carcinoma of the lung. The Lung Cancer Study Group. Ann Surg 202:335–341

    Google Scholar 

  7. Shields TW, Hoggins GA, Humphrey EW, Matthews MJ, Keehn RJ (1982) Prolonged intermittent adjuvant chemotherapy with CCNU and hydroxyurea after resection of carcinoma of the lung. Cancer 50:1713–1721

    Article  CAS  PubMed  Google Scholar 

  8. Hara N, Ohta M, Ichinose Y, Motohiro A, Ishida T, Noge S, Miyake J (1985) Surgical adjuvant chemotherapy for lung cancer. In: Ishigami J (ed) Recent advances in chemotherapy: proceedings of the 14th International Congress on Chemotherapy University of Tokyo Press, Tokyo, pp 155–157

    Google Scholar 

  9. Gros P, Neriah YB, Croop JM, Housman DE (1986) Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 323:728–731

    Article  CAS  PubMed  Google Scholar 

  10. Chen CJ, Chin JE, Veda K, Clark DP, Pastan I, Gottesman MM, Roninson IB (1986) Internal duplication and homology with bacterial transport proteins in the mdrl (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47:381–389

    Article  CAS  PubMed  Google Scholar 

  11. Licht T, Pastan I, Gottesman M, Hermann F (1994) P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells. Ann Hematol 69:159–171

    Article  CAS  PubMed  Google Scholar 

  12. Ling V (1995) P-glycoprotein; its role in drug resistance. Am J Med 99 (Suppl):31S-34S

    Article  CAS  PubMed  Google Scholar 

  13. World Health Organization (1982) Histological typing of lung tumors (WHO), edn 2. Am J Clin Pathol 77:123–136

    Google Scholar 

  14. Grogan T, Dalton W, Rybski J, Spier C, Meltzer P, Richter L, Gleason M, Pindur J, Cline A, Scheper R, Tsuruo T, Salmon S (1990) Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies. Lab Invest 63:815–824

    CAS  PubMed  Google Scholar 

  15. Giorno R (1984) A comparison of two immunoperoxidase staining methods based on the avidin-biotin interaction. Diagn Immunol 2:161–166

    CAS  PubMed  Google Scholar 

  16. Dixon WJ (ed) (1988) BMDP statistical software. University of California Press, Berkeley, B34, pp 187–220

    Google Scholar 

  17. Kaplan EL, Meier P (1965) Non-parametric estimation from incomplete observation. J Am Stat Assoc 53:203–224

    Google Scholar 

  18. Petp R, Pike MC, Armitage P, Brestlow NE, Cox, DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 35:1–39

    Google Scholar 

  19. Cox DR (1972) Regression models and life tables. J R Stat Soc B 34:187–220

    Google Scholar 

  20. Gottesman MM, Pastan I, Ambudkar SV (1996) P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 6:610–617

    Article  CAS  PubMed  Google Scholar 

  21. Bosch I, Croop MJ (1996) P-glycoprotein multidrug resistance and cancer. Biochim Biophys Acta 1288:F37-F54

    PubMed  Google Scholar 

  22. Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S, Mori S (1988) Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK16. Cancer

  23. Sugawara I (1990) Expression and functions of P-glycoprotein (mdrl gene product) in normal and malignant tissues. Acta Pathol Jpn 40:545–553

    CAS  PubMed  Google Scholar 

  24. Mizoguchi T, Yamada K, Furukawa T, Hidaka K, Hisatsugu T, Shimazu H, Tsuruo T, Sumizawa T, Akiyama S (1990) Expression of the MDR1 gene in human gastric and colorectal carcinomas. J Natl Cancer Inst 82:1679–1683

    Article  CAS  PubMed  Google Scholar 

  25. Verrelle P, Meissonnier F, Fonck Y, Feillel V, Dionet C, Kwaitkowski F, Plagne R, Chassagne J (1991) Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 83:111–116

    Article  CAS  PubMed  Google Scholar 

  26. Scotto KW, Bielder JL, Melera PW (1986) Amplification and expression of genes associated with multidrug resistance in mammalian cells. Science 232:751–755

    Article  CAS  PubMed  Google Scholar 

  27. Bell DR, Gerlach JH, Kartner N, Buick RN, Ling V (1985) Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance J Clin Oncol 3:311–315

    CAS  PubMed  Google Scholar 

  28. Rutledge M, Robey-Cafferty S, Silva E, Bruner J (1989) Monoclonal antibody (C219) detection of the multidrug resistant protein (P-glycoprotein) in routinely processed tissues: a study of 36 cases of ovarian carcinoma. Lab Invest 60:80A

    Google Scholar 

  29. Chan HS, Haddad G, Thorner PS, Deboer G, Lin YP, Ondrusek N, Yeger H, Ling V (1991) P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325:1608–1614

    Article  CAS  PubMed  Google Scholar 

  30. Dalton WS (1993) Drug resistance modulation in the laboratory and the clinic. Semin Oncol 20:64–69

    CAS  PubMed  Google Scholar 

  31. Wishart GC, Plumb JA, Going JJ, McNicol AM, McArdle CS, Tsuruo T, Kaye SB (1990) P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer 62:758–761

    CAS  PubMed  Google Scholar 

  32. Chen HSL, Haddad G, Thorner PS, DeBoer G, Lin YP, Ondrusek N, Yeger H, Ling V (1991) P-glycoprotein expression as a predictor of the outcome of therapy for neuroblstoma. N Engl J Med 325:1608–1614

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery II, Faculty of Medicine, Kyushu University, 3-1-1 Maidashi, Higashi-ku, 812-8582, Fukuoka, Japan

    Hideki Yokoyama, Teruyoshi Ishida, Kenji Sugio, Takashi Inoue & Keizo Sugimachi

Authors
  1. Hideki Yokoyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Teruyoshi Ishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenji Sugio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takashi Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Keizo Sugimachi
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported in part by a Grant-in-Aid for General scientific Research (No. 03670659) from the Ministry of Education, Science and Culture of Japan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yokoyama, H., Ishida, T., Sugio, K. et al. Immunohistochemical evidence that P-glycoprotein in non-small cell lung cancers is associated with shorter survival. Surg Today 29, 1141–1147 (1999). https://doi.org/10.1007/BF02482262

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02482262

Key Words

Search

Navigation